# SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
# 上海君實生物醫藥科技股份有限公司

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Resolutions of the Twenty-third Meeting of the Fourth Session of the Board of Directors" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only.

By order of the Board
**Shanghai Junshi Biosciences Co., Ltd.***
**Mr. Xiong Jun**
*Chairman*

Shanghai, the PRC, 23 September 2026

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.*

* *For identification purposes only*

# Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Resolutions of the Twenty-third Meeting of the Fourth Session of the Board of Directors



**I. Convening of the Board Meeting**

The twenty-third meeting of the fourth session of the board of directors (the "Board") of Shanghai Junshi Biosciences Co., Ltd. (the "Company") was convened on 23 September 2026 by way of on-site meeting combined with voting by correspondence. The notice of this meeting was sent to all directors by email on 18 September 2026. The meeting was chaired by Mr. Xiong Jun, the chairman of the Board. 14 directors were to attend, and 14 directors attended the meeting. The convening and holding procedures of this meeting complied with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*, and the resolutions passed at the meeting are legal and valid.

**II. Consideration of Resolutions at the Meeting of the Board**

**(I) "Resolution on the Fulfillment of the Conditions for the First Exercise Period of the First Grant under the 2025 A Share Option Incentive Scheme and the Cancellation of Partial Share Options" was considered and approved**

In accordance with the relevant laws and regulations and the relevant provisions of the 2025 A Share Option Incentive Scheme of the Company (the "Incentive

Scheme"), the Board considers that the conditions for the first exercise period of the share options granted under the first grant of this Incentive Scheme of the Company have been fulfilled. Given that certain participants of the first grant under the 2025 A Share Option Incentive Scheme of the Company have resigned, and certain participants cannot fully exercise their share options due to their personal performance assessment results, the Company proposes to cancel a total of 1,740,000 share options that have been granted but not yet exercised. The Board approves that the 205 participants who satisfy the exercise conditions may exercise their share options on an individual basis within the prescribed exercise period, where the number of exercisable share options is 11,467,500, and 1,740,000 share options shall be cancelled.

This resolution has been considered and approved by the Remuneration and Appraisal Committee of the Board of the Company, which agreed to submit it to the Board for consideration.

Voting Result: For: 13, Against: 0, Abstain: 0. The connected director Xiong Jun abstained from voting on this resolution.

For details, please refer to the announcement published by the Company on the same day on the website of the Shanghai Stock Exchange (www.sse.com.cn).

**(II) "Resolution on the Reserved Grant of Share Options to the Participants for the 2025 A Share Option Incentive Scheme" was considered and approved**

In accordance with the relevant laws and regulations, the relevant provisions of the 2025 A Share Option Incentive Scheme of the Company, and the authorization granted by the 2025 first extraordinary general meeting of the Company to the Board to handle matters in relation to the share option incentive, the Board considers that the Company and the participants for this reserved grant satisfy the conditions for the grant, that there are no circumstances under which the grant cannot be made or the relevant persons are prohibited from becoming participants, and that the conditions for the reserved grant as stipulated under this Incentive Scheme have been fulfilled. The Board approves to designate 23 September 2026 as the grant date of the reserved grant, and to grant 715,000 share options to 16 participants who satisfy the grant conditions at an exercise price of RMB46.67 per share.

This resolution has been considered and approved by the Remuneration and Appraisal Committee of the Board of the Company, which agreed to submit it to the Board for consideration.

Voting Result: For: 14, Against: 0, Abstain: 0.

For details, please refer to the announcement published by the Company on the same day on the website of the Shanghai Stock Exchange (www.sse.com.cn).

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

24 September 2026